Helicobacterpylori eradication regimens in an antibiotic high‐resistance European area: A cost‐effectiveness analysis
Open Access
- 6 November 2019
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 25 (1) , e12666
Abstract
Introduction: Helicobacter pylori infection (H pylori‐I) affects more than half of the global population and consists an important burden to public health and healthcare expenditures, by contributing to many diseases' pathogenesis.Aim: This study aimed to evaluate the current nonbismuth quadruple eradication regimens in a high antibiotic resistance area, such as Greece, concerning their cost‐effectiveness, especially during financial crisis period.Materials and methods: Eight hundred and nine patients who received eradication treatment against H pylori‐I were included to evaluate five different regimens, using amoxicillin, clarithromycin, and metronidazole as antibiotics and one proton‐pump inhibitor, based on their current eradication rates. Regimes compared 10‐day concomitant use of (a) pantoprazole or (b) esomeprazole; 10‐day sequential use of (c) pantoprazole or (d) esomeprazole; and 14‐day hybrid using esomeprazole. Cost‐effectiveness analysis ratio (CEAR) and incremental cost‐effectiveness ratios were calculated taking into account all direct costs and cases who needed second‐line treatment. Additionally, sensitivity analysis was performed to predict all potential combinations.Results: Ten‐day concomitant regimen with esomeprazole was characterized by the lowest CEAR (179.17€) followed by the same regimen using pantoprazole (183.27€). Hybrid regimen, although equivalent in eradication rates, was found to have higher CEAR (187.42€), whereas sequential regimens were not cost‐effective (CEAR: 204.12€ and 216.02€ respectively).Discussion: This is the first study evaluating the cost‐effectiveness of H pylori‐I treatment regimens in a high clarithromycin‐resistance (≈26.5%) European area, suggesting the 10‐day concomitant regimen with generics using esomeprazole 40 mg as the most appropriate one. National and regional guidelines should include cost‐effectiveness in their statements, and further studies are required to clarify the necessity of a wide “test and treat” policy for H pylori‐I.Keywords
This publication has 28 references indexed in Scilit:
- Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across EuropeAlimentary Pharmacology & Therapeutics, 2015
- Concomitant versus sequential therapy for the treatment ofHelicobacter pyloriinfection: a Greek randomized prospective studyScandinavian Journal of Gastroenterology, 2015
- Helicobacter pylori infection, dementia and primary open-angle glaucoma: are they connected?BMC Ophthalmology, 2015
- The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in GreeceDigestion, 2014
- Treatment ofHelicobacter pyloriinfection: Meeting the challenge of antimicrobial resistanceWorld Journal of Gastroenterology, 2014
- Does Helicobacter pylori Infection Increase Incidence of Dementia? The Personnes Agées QUID StudyJournal of the American Geriatrics Society, 2012
- Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumptionGut, 2012
- Sensitivity Analysis in Cost-Effectiveness StudiesPharmacoEconomics, 2011
- The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic ReviewHelicobacter, 2011
- A Report Card to Grade Helicobacter pylori TherapyHelicobacter, 2007